

# INDEX

## A

- Acid guanidinium-thiocyanate-phenol-chloroform (AGPC) extraction ..... 115–121
- Affinity enrichment ..... 1255–134
- AFM. *See* Atomic force microscope (AFM)
- Aldefluor assay ..... 2, 7, 8, 20
- Aldehyde dehydrogenase (ALDH) ..... 2, 6–10, 15–18, 20, 21, 27–29, 34, 37, 64, 222
- Anesthesia ..... 153, 165, 169, 175, 179, 182–185, 223, 225, 226, 228
- Antibiotic selection ..... 145–146, 149, 157, 158
- Antibody capture ..... 128–130
- Atomic force microscope (AFM) ..... 232–240, 242–244
- ATP-binding cassette transporters (ABC transporter) ..... 17, 74, 75, 268, 269

## B

- Basal ..... 1, 2, 6, 7, 10, 13–15, 51, 53, 162, 163, 170, 171, 188
- Biomarker ..... 5, 37, 38
- Biosafety ..... 137, 143, 150, 184
- Branching morphogenesis ..... 187
- BRCA ..... 13–15
- Breast cancer ..... 1–39, 52, 62, 64, 67, 116, 125, 134, 213–220, 222, 223, 233, 268, 269
- Breast cancer resistance protein (BCRP1/ABCG2) ..... 17, 269

## C

- Cancer stem cells (CSCs) ..... 1–39, 63–65, 221–228, 268–270
- CD24 ..... 1–2, 7, 21–10, 12–14, 16, 25, 28–30, 37, 70, 162, 222–224
- CD44 ..... 19, 20, 22, 70, 162, 224
- CD29 ( $\beta$ 1 integrin) ..... 7, 9
- CD49f ( $\alpha$ 6 integrin) ..... 7, 19
- Cell isolation ..... 90
- Cell surface antigen ..... 7, 63, 69, 77, 80
- CHAPS ..... 126–129, 131–133
- Chemotherapy ..... 13, 15–18, 29, 30, 36, 37, 39, 65, 74, 75, 259, 268–270
- Circulating tumor cell (CTC) ..... 21–25, 39, 203
- Cleared fat pad ..... 26, 27, 163, 166–168, 188

- Common acute lymphoblastic leukaemia antigen (CALLA/CD10) ..... 64
- Confocal microscopy ..... 195–199, 202, 207, 209
- Cre driver ..... 188, 189, 193, 200, 201, 203, 205
- Cre-loxP* ..... 61
- Cre/lox technology ..... 187–209
- Crosslinking ..... 127, 128, 130, 133
- CSCs. *See* Cancer stem cells (CSCs)

## D

- Diagnosis ..... 36
- Differential equation ..... 248–250, 253, 256, 259–261, 264
- Differentiation ..... 1, 4–8, 11, 12, 31, 38, 75, 83, 161, 162, 187, 188, 230, 247–264
- Disease ..... 2, 3, 13, 22, 23, 25, 29, 35, 36, 38, 153, 176, 214, 222, 247, 268

## E

- ECM. *See* Extracellular matrix (ECM)
- Embryonic explant culture ..... 52, 54, 58–61
- Embryonic mammary gland ..... 61
- Embryonic mammary progenitor cell ..... 51–61
- Endocrine therapy ..... 13, 28
- Environment ..... 6, 10, 161, 169, 174, 188, 244, 247
- EpCAM ..... 7, 9, 10, 21, 22, 24, 64, 162
- Epithelial membrane antigen (EMA) ..... 64
- Epithelial specific antigen (ESA) ..... 11, 64, 80
- Epithelial-to-mesenchymal transition (EMT) ..... 3, 9–11, 13, 15, 19, 21
- ESA. *See* Epithelial specific antigen (ESA)
- Estrogen ..... 1, 12, 27, 28, 34, 75, 201, 202, 206, 222
- Extracellular matrix (ECM) ..... 8, 19, 61, 162, 219, 231, 233, 241

## F

- FACS. *See* Fluorescent activated cell sorting (FACS)
- Filter assisted sample preparation (FASP) ..... 116, 119–120
- Flank dissection ..... 57
- Flow cytometry ..... 7, 8, 68, 146–147, 158, 167, 219
- Fluorescence ..... 8, 9, 24, 57, 66, 69, 71, 77, 80, 89, 120, 147, 158, 199, 202, 204, 215, 218–219, 223–225

Fluorescent activated cell sorting (FACS) ..... 8, 63–71,  
 73, 76, 89, 90, 142, 146, 157, 158, 191, 204, 207,  
 224–225, 228. *See also* Sorting

Fluorochrome ..... 8, 65, 66, 68, 69, 71  
 Freezing medium ..... 148

**G**

Gene expression profile ..... 3, 9, 13, 22  
 Genomics ..... 4, 18, 35, 83, 93, 94, 110, 111, 139, 142  
 Gland development ..... 61, 174, 183, 201  
 Green fluorescent protein (GFP) ..... 52, 58–60,  
 141, 143, 146, 147, 158, 163, 177, 191, 192, 199,  
 206–209, 215, 219

**H**

HER2 ..... 13, 15–17, 22, 31, 32, 36–38  
 High throughput sequencing (HTS) ..... 83–113  
 Hoechst 33342 ..... 75–77, 79, 80  
 Hormone ..... 1, 12, 13, 28, 36, 173  
 Human breast ..... 6, 7, 9, 15–17, 19, 20, 22,  
 26–29, 31, 63, 64, 78, 79, 174, 184, 221, 233  
 biopsies ..... 233  
 Human immunodeficiency virus (HIV) ..... 137, 138,  
 141, 142, 148, 150, 152–154  
 Human in mouse model ..... 174  
 Humanised mice ..... 173–185  
 Humanization ..... 173–185  
 Human mammary epithelial cells ..... 174, 180–182, 222

**I**

Imaging ..... 20, 24, 39, 59, 169, 202, 224,  
 226–227, 232, 243  
 Immune-compromised NOD/SCID mouse ..... 5  
 Immunoaffinity enrichment ..... 124, 125  
 Immuno-multiple reaction monitoring  
 (iMRM) ..... 125, 130, 131  
 Immunostaining ..... 52  
 Infection ..... 137, 145–147, 149–150, 153,  
 156–159, 177, 185, 228, 256  
 Integrin ..... 7, 19, 35, 75, 162  
 Isotype ..... 8, 69

**J**

Jackson ..... 61, 189–191, 203

**K**

Keratin ..... 33, 52, 53, 120

**L**

Lentiviral vectors ..... 137, 138, 140, 143–144,  
 147, 150, 152, 154–159  
 Lentivirus ..... 150–152, 156, 158, 215

Library enrichment ..... 95–97, 109  
 Library preparation ..... 84–89, 93–95, 109–111, 113  
 Limiting dilution ..... 52, 74, 75, 163, 170, 225  
 Lineage tracing ..... 14, 51, 187–209  
 Living mammary tissues ..... 231–245  
 Luminal cells ..... 64

**M**

Magnetic beads ..... 23, 112, 125, 127, 128, 132–134  
 Mammary bud ..... 51, 52, 200  
 Mammary epithelial cells ..... 2, 6, 7, 9, 14, 19, 20,  
 34, 51, 63, 69, 71, 77, 137–159, 161–185, 222  
 Mammary fat pad ..... 2, 7, 14, 16, 26, 27, 34,  
 64, 161–171, 178–181  
 Mammary-forming region ..... 51, 55–57  
 Mammary gland ..... 2, 7, 14, 16, 31, 33, 51, 52, 63, 74,  
 77, 162, 163, 169, 170, 173–185, 187–210, 221, 222  
 Mammary primordium ..... 51, 52  
 Mammoplasty ..... 142, 148, 174, 178  
 Mammospheres/tumorspheres ..... 9, 16, 29, 30, 35, 149  
 Mass spectrometry (MS) ..... 116, 123–125,  
 129, 131, 132  
 Mathematical model ..... 247–264  
 Matrigel ..... 15, 21, 163, 164, 167, 170, 175,  
 180, 182, 225, 228  
 Mechanobiology ..... 232  
 Medium ..... 52–57, 59–61, 71, 76, 111,  
 141–151, 153, 155, 159, 163, 164, 166, 167, 169, 185,  
 214, 215, 217–220, 223, 224  
 Mesenchymal-to-epithelial transition (MET) ..... 3, 9–13,  
 21, 22, 39  
 Metastasis ..... 2–3, 10, 30–12, 19–22, 34, 35,  
 37, 213, 222, 223, 225  
 MicroRNAs (miRNAs) ..... 9, 10, 34–35, 38, 75  
 Modelling ..... 247–264  
 Mouse ..... 2, 5–7, 11, 12, 14–16, 18–20,  
 26, 31, 32, 34, 51–61, 73, 74, 80, 140, 161–171,  
 173–185, 187–190, 192–195, 200, 201, 204, 205,  
 222, 225, 226, 257  
 Mouse mammary fat pad ..... 2, 162  
 Mouse strain ..... 54, 55, 163, 169, 189, 190, 200, 201  
 MUC-1 ..... 64. *See also* Epithelial membrane antigen  
 Multiple reaction monitoring mass spectrometry  
 (MRM-MS) ..... 124, 125, 129, 130  
 Myoepithelial cells ..... 1, 64

**N**

Niche ..... 33, 162, 213–219, 221–228

**O**

Organoids ..... 52, 148, 174, 176, 177, 180–182  
 Outgrowth ..... 161–163, 165, 168–171, 189,  
 204–206, 209, 223

**P**

Packaging vector.....138  
 Patient derived xenograft (PDX).....3, 26–29  
 Peptide.....8, 116, 119, 120, 123–134  
 Placode.....51, 52, 57–61  
 Population dynamics.....249, 256  
 Pregnancy.....1, 2, 63, 74, 161, 187, 188, 194, 195, 204, 206, 209, 221, 222  
 Progenitor cell.....2, 4, 7, 13–16, 18, 20, 30, 31, 33, 51–61, 63, 188, 222, 253, 260, 261, 263, 264  
 Promoter.....75, 138, 140, 149, 154, 156–158, 189, 200  
 Protein quantification.....125  
 Proteomics.....115–121

**R**

Radiotherapy.....17, 36, 65, 269  
 Recombination.....154, 155, 189–191, 193–195, 201, 203, 205, 206  
 Regeneration.....162, 187, 257, 260, 269  
 Reporter.....52, 55, 61, 187–210  
 Resistance.....3, 11, 15–19, 22, 28, 30–32, 34, 37, 65, 74, 75, 139, 140, 149, 153, 155, 158, 257, 268–270  
 Resolubilization.....116, 120

**S**

Sample preparation.....85, 87, 88, 93, 95, 97, 99, 109, 111, 116, 235–236  
 Sample quality control.....111  
 Self-renew.....2–8, 11, 15, 18, 20, 21, 27, 29–33, 38, 39, 52, 161, 163, 247–264  
 Sensitivity.....17, 23, 25, 29, 85, 86, 88, 95, 98, 104–108, 111, 113, 123–125, 154, 201, 232, 233, 237, 239, 240, 243, 244  
 Sequencing library.....84, 90, 93, 98, 112  
 Shotgun proteomics.....115–121  
 Side population (SP).....6, 7, 16, 17, 73–80  
 Single cell genome.....83–113  
 Single cell suspension.....66, 76, 77, 163, 167, 170  
 Sorting.....25, 63–71, 77, 79, 80, 89, 163, 188, 191, 223–225, 228  
 Spatial resolution.....232, 233  
*s-SHIP-GFP* reporter mice.....55, 59

Stable isotope dilution mass spectrometry (SID-MS).....124  
 Stem cell.....1–39, 52, 59, 63–71, 73, 74, 79, 83, 140, 152, 161–163, 165, 170, 188, 189, 203–206, 221–228, 247–249, 253, 254, 257, 259–261, 263, 265, 267–270  
 Stem cell dynamics.....261  
 Stemness.....3–6, 34, 269  
 Stroma.....33, 75, 77, 173, 174, 176–178, 180, 182, 185, 187, 188, 214–217, 219  
 Structured population models.....259–265

**T**

Tagmentation.....94, 95  
 Tamoxifen.....28, 34, 65, 188, 190, 192–195, 201, 204–206  
 Targeted mass spectrometry.....123  
 Terminal ductal lobular units (TDLU).....1  
 3D.....15, 188, 199–200, 207, 209, 214–219, 232, 233, 236  
 Tissue digestion.....77, 163  
 Titration.....65, 68, 127, 132, 134, 140–142, 144–148, 150, 158  
 Transduction.....30, 33, 137–159, 247  
 Transfection.....138, 143, 144, 157, 159  
 Transgene.....31, 137, 139, 140, 148, 153, 155–158, 200, 203  
 Transplantation.....2, 5, 6, 8, 14, 26, 27, 52, 63, 74, 75, 161–171, 188, 258–260  
 Tumorigenesis.....2, 4, 5, 12–15, 19, 31, 174, 222  
 Tumor tissues.....8, 16, 18, 21, 26, 36, 117–118  
 Tumor heterogeneity.....3–5

**V**

Vesicular stomatitis glycoprotein (VSV G).....138, 139, 141, 144, 150, 159  
 Viral particles.....149, 152, 177  
 Viral titers.....144, 145, 157

**W**

Wholemout.....191

**X**

Xenograft.....3, 5, 7, 9, 15, 22, 26–29, 32–34, 180